fbpx

Research

RESEARCH

ST GEORGE CANCER CENTRE

At Sydney’s St George Hospital, CanCare supports research into the development of new treatments of cancer micro-metastases. Working under A/Prof. Yong Li, Yong’s team work to identify the mechanisms of prostate & ovarian cancer metastasis, and investigate drug (chemo) and radio-resistance in tumour ‘micro-environments’, and the associated stem cell changes.

 

The aim of this work is to develop targeted cancer therapies to control prostate and ovarian cancers.

 

New therapies mean patients are more likely to live longer and with less side effects, as the treatments have a greater impact on the cancer.

 

A number of promising areas of research are underway.

 

Some of the published research includes:

• Investigation of the ways prostate & ovarian cancer metastasise (spread),  and the drug and radio-resistance associated with tumour micro-environments, and cancer stem cell (CSC ) & epithelial cell changes

• Investigation of ‘novel biomarkers’ in human body fluids, looking for markers that may indicate cancer. This work offers hope of new methods of early diagnosis, so critical in many cancers where the symptoms only become known when it’s too late.

Targeted therapies

mean that patients are likely to live longer and with a higher quality of life,
as the treatments have less risk, less side effects and a greater impact on the cancer.

PUBLISHED

RESEARCH

Epithelial cell adhesion molecule (EpCAM) is associated with prostatecancer metastasis and chemo/radioresistance

Jie Ni, PaulCozzi, Jingli Hao, Julia Beretov, Lei Chang, Wei Duan, Sarah Shigdar, Warick Delprado, Peter Graham, Joseph Bucci, John Kearsley, Yong Li; International Journal of Biochemistry & Cell Biology (2013)

CD44 Variant 6 is Associated With Prostate Cancer Metastasis andChemo-/Radioresistance

Jie Ni, Paul J. Cozzi, Jing L. Hao,Julia Beretov, Lei Chang, Wei Duan, Sarah Shigdar, Warick J. Delprado, Peter H. Graham, Joseph Bucci, John H. Kearsley, and Yong Li; The Prostate (2014)

Cancer Stem Cells in Prostate Cancer Chemoresistance Current Cancer Drug Targets

Jie Ni, Paul Cozzi, Jingli Hao, Wei Duan, Peter Graham, John Kearsley and Yong Li (2014)

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance Crit Rev Oncol/Hematol

Lei Changa, Peter H. Grahama, Jie Nia, Jingli Haoa, Joseph Buccia, Paul J. Cozzib, Yong Lia (2015)

Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo

Jie Ni, Paul Cozzi, Julia Beretov, Wei Duan, Joseph Bucci, Peter Graham and Yong Li (2018)

Close Bitnami banner
Bitnami